<DOC>
	<DOCNO>NCT02652377</DOCNO>
	<brief_summary>This randomize , double-blind study ass safety , pharmacokinetics efficacy single multiple dose ( ) orally QD administer EDP-494 healthy volunteer ( HV ) treatment-naive subject GT1/3 chronic hepatitis C ( CHC ) infection .</brief_summary>
	<brief_title>EDP-494-001 : A Study EDP-494 Healthy Subjects Hepatitis C Patients</brief_title>
	<detailed_description>The first phase explore single ascend dos EDP-494 ( active drug placebo ) healthy subject . A 'fasted ' v 'fed ' two-part cohort also assess food effect . The second phase involve multiple ascend dos ( active drug placebo ) 14 day healthy subject . The third , proof concept , phase assess two different dos 14 day Hepatitis C patient . Each cohort within phase consist 8 subject randomize either EDP-494 placebo 3 1 ratio , exception food effect cohort , consist 10 subject randomise 4 1 ratio .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Inclusion Criteria Healthy Volunteers ( SAD MAD Phases ) : Healthy male female subject ethnic origin age 18 55 year , inclusive . Female subject must nonchildbearing potential . All male participant vasectomy must use effective contraception Day 1 90 day last dose study drug . Body mass index 18 30 kg/m2 minimum body weight 50 kg . An informed consent document sign date subject . Exclusion Criteria Healthy Volunteers ( SAD MAD Phases ) : Clinically relevant evidence history illness disease Pregnant nursing female . History febrile illness within 7 day prior first dose study drug subject evidence active infection . A positive urine drug screen screen Day 1 . Any condition possibly affect drug absorption ( e.g. , gastrectomy ) . History regular alcohol consumption Participation clinical trial within 30 day prior study drug administration . Use prescription drug , nonprescription drug , dietary supplement , herbal supplement , hormonal therapy/replacement CYP3A4 substrates , inducer inhibitor within 14 day prior first dose study medication Inclusion Criteria HCVInfected Subjects ( POC Phase ) : Males female age 18 year less 70 year . Female subject must nonchildbearing potential . All male participant vasectomy must use effective contraception Day 1 90 day last dose study drug . Body mass index 18 36 kg/m2 minimum body weight 50 kg . Treatment naïve subject chronic HCV infection , HCV GT1 ( include 1a , 1b , mixed subtypes GT1 ) GT3 . HCV RNA ≥100,000 IU/mL screen . An informed consent document sign date subject . Exclusion Criteria HCVInfected Subjects ( POC Phase ) : Women childbearing potential ( WOCBP ) . Pregnant nursing female . History febrile illness within 7 day prior first dose study drug . A positive urine drug screen screen unless approve prescription . History participation clinical trial polymerase inhibitor previous treatment polymerase inhibitor , least one dose polymerase inhibitor consume . Subjects dose placebo clinical trial may enrol study . Clinically significant electrocardiogram abnormality QTcF great 450 msec male 470 msec female either screen baseline , prior history QT abnormality . Coinfection HIV1 , HIV2 HBV . Have clinically significant laboratory abnormality screen : Absolute neutrophil count ( ANC ) &lt; 1500/mm2 ( 1.5 x 109L ) Platelets &lt; 90,000/mm2 ( 90 x 109L ) Hemoglobin &lt; 13g/dL male &lt; 12g/dL female Serum creatinine &gt; 1.5 x upper limit normal ( ULN ) creatinine clearance &lt; 50 mL/min ; estimate cockcroft Gault formula [ ( 140age ) x weight ( kg ) /72 x serum creatinine ( mg/dL ) , female multiply 0.85 ] Total bilirubin great ULN Serum alanine transaminase ( ALT ) &gt; 5 x ULN Serum aspartate aminotransferase ( AST ) &gt; 5 x ULN Alkaline phosphatase &gt; 1.25 x ULN Pancreatic Amylase &gt; 1.1 x ULN Alpha fetoprotein ( AFP ) &gt; 50 ng/mL unless liver image study ( CT , MRI ) show clinically significant lesion within 6 month prior first dose study drug . Patients evidence cirrhosis ; cirrhosis define one following : ) biopsy show cirrhosis ( Knodell score &lt; 3 , Metavir score &lt; 3 , Ishak score &lt; 4 ) ; b ) Fibroscan evaluation within 6 month prior screen liver stiffness score &gt; &lt; 12.5 kPa . Other significant , unstable uncontrolled medical history , neurological , endocrine , malignancy , renal , psychiatric , respiratory , cardiac , gastrointestinal , allergic , immunological , etc . disease . Use concomitant medication , include vitamin herbal dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>